Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.21 USD
+0.01 (0.31%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $3.21 0.00 (0.00%) 7:08 PM ET
1-Strong Buy of 5 1
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
FULC 3.21 +0.01(0.31%)
Will FULC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FULC
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Here's Why Bausch Health Stock Gained 14.7% in a Week
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
Other News for FULC
Fulcrum reduces its workforce
Largest borrow rate increases among liquid names
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)